Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.

Autor:	Carreón Guarnizo E; CSUR Esclerosis Múltiple y Unidad de Neuroinmunología Clínica, Servicio de Neurología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain. Electronic address: strcg_2@hotmail.com., Hernández Clares R; CSUR Esclerosis Múltiple y Unidad de Neuroinmunología Clínica, Servicio de Neurología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain., Castillo Triviño T; Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain., Meca Lallana V; Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario de La Princesa, Madrid, Spain., Arocas Casañ V; Servicio de Farmacia, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain., Iniesta Martínez F; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain., Olascoaga Urtaza J; Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain., Meca Lallana JE; CSUR Esclerosis Múltiple y Unidad de Neuroinmunología Clínica, Servicio de Neurología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain.
Jazyk:	angličtina
Zdroj:	Neurologia (Barcelona, Spain) [Neurologia (Engl Ed)] 2022 Apr; Vol. 37 (3), pp. 178-183. Date of Electronic Publication: 2021 Feb 26.
DOI:	10.1016/j.nrleng.2018.12.021
Abstrakt:	Introduction: Neuromyelitis optica spectrum disorders (NMOSD) are immune-mediated inflammatory disorders of the central nervous system involving astrocytes, B lymphocytes, anti-aquaporin 4, and such inflammatory mediators as interleukin-6. Several immunosuppressants are used in their treatment. Tocilizumab, an interleukin-6 receptor antagonist, may be a treatment option. Method: We performed an observational, retrospective study analysing parameters of effectiveness (annualised relapse rate, disability, and radiological progression) and safety of tocilizumab in patients with NMOSD in whom previous immunosuppressant treatment had failed. We aimed to evaluate the effectiveness and safety of tocilizumab in clinical practice in patients with NMOSD not responding to other immunosuppressants. Results: Five patients with NMOSD were analysed. Sixty percent of patients were women; mean age at diagnosis was 50±5.3 years and mean progression time was 4.5±3.6 years. Previously administered immunosuppressants were rituximab (in all 5), cyclophosphamide (2), and azathioprine (1). Mean time of exposure to tocilizumab was 2.3±1 years. Mean annualised relapse rate was 1.8±1.3 in the year prior to the introduction of tocilizumab and 0.2±0.4 the year after (P<.05), representing a reduction of 88.9%. Conclusions: In our experience, tocilizumab is safe and effective in patients with NMOSD showing no response to other immunosuppressants. (Copyright © 2019 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu